NCT07179575View on ClinicalTrials.gov

Study of LW231 in Participants With Chronic Hepatitis B

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

270

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

March 31, 2027

Study Completion Date

November 30, 2027

Conditions
Chronic HBV Infection
Interventions
DRUG

LW231

LW231 tablets

DRUG

LW231 placebo

LW231 placebo tablets

Trial Locations (2)

Unknown

RECRUITING

The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou

NOT_YET_RECRUITING

The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou

All Listed Sponsors
lead

Shanghai Longwood Biopharmaceuticals Co., Ltd.

INDUSTRY

NCT07179575 - Study of LW231 in Participants With Chronic Hepatitis B | Biotech Hunter | Biotech Hunter